About 30 results found for searched term "HA14-1" (0.093 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M3753 | HA14-1 | Bcl-2 |
| HA14-1 is a Bcl-2 inhibitor that is widely used for studies of apoptosis with IC50 of ~9 μM. | ||
| M17955 | (13alpha,14beta,17alpha,20S)-5alpha-Lanosta-8,24-Dien-3beta-Ol | Others |
| (13alpha,14beta,17alpha,20S)-5alpha-Lanosta-8,24-Dien-3beta-Ol | ||
| M1749 | Gefitinib | EGFR/HER2 |
| ZD-1839, Iressa | ||
| Gefitinib (ZD1839) is an EGFR tyrosine kinase and Akt phosphorylation inhibitor. Gefitinib significantly down-regulates CD47 expression and increases DC phagocytosis in non-small cell lung cancer cells such as PC9, H1437 and H1573. Gefitinib combined with CD47 antibody can enhance the phagocytosis of macrophages. | ||
| M2593 | Siramesine hydrochloride | Sigma Receptor |
| Lu 28-179 | ||
| Siramesine (Lu 28-179) hydrochloride is an effective sigma-2 receptor agonist. Siramesine has a nanomolar affinity for sigma-2 receptors (IC50=0.12 nM) and is 140 times more selective for sigma-2 receptors (IC50=17 nM). Siramesine has xC-system inhibitory activity associated with iron death. | ||
| M2368 | Aclidinium Bromide | AChR/AChE |
| LAS 34273; LAS-W 330 | ||
| Aclidinium Bromide is a novel long-acting muscarinic antagonist that binds to the human muscarinic receptors AChR M1, M2, M3, M4, and M5 with Ki values of 0.1 nM, 0.14 nM, 0.14 nM, 0.21 nM, and 0.16 nM, respectively. It can be used in chronic obstructive pulmonary disease (COPD) studies. | ||
| M2592 | Siramesine | Sigma Receptor |
| Lu 28-179 | ||
| Siramesine (Lu 28-179) is a potent sigma-2 receptor agonist. Siramesine has a subnanomolar affinity for sigma-2 receptors (IC50=0.12 nM) and exhibits a 140-fold selectivity for sigma-2 receptors over sigma-1 receptors (IC50=17 nM). Siramesine triggers cell death through destabilisation of mitochondria, but not lysosomes. | ||
| M4058 | 11-oxo-mogroside-V | ROS |
| 11-Oxo-Mogroside V is a natural sweetener with strong antioxidant activity. 11-OXo-Mogroside V had a significant inhibitory effect on reactive oxygen species, and the EC50 of O2-, H2O2 and *OH were 4.79, 16.52 and 146.17 μg/mL, respectively. | ||
| M6101 | Atezolizumab | PD-1/PD-L1 |
| MPDL3280A,Anti-PD-L1；Tecentriq | ||
| Atezolizumab (atezolizumab) is a humanized anti-PD-L1 monoclonal antibody that inhibits PD-L1 signaling with PD-1 and B7-1 and restores tumor-specific T-cell immunity. However, it does not affect the interaction of PD-L2 with PD-1. MW: 145 KD. atezolizumab reacts with murine PD-L1 (for human and non-humanized mice). | ||
| M6102 | Pembrolizumab | PD-1/PD-L1 |
| Lambrolizumab; MK-3475；Keytruda | ||
| Pembrolizumab (pembrolizumab) is a humanized anti-PD-1 monoclonal antibody that blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2. It has immune checkpoint inhibitory activity and antitumor activity. MW: 146.286 KD.(Pembrolizumab does not recognize murine PD-1 protein, humanized mice or mice expressing human PD-1 gene are required). | ||
| M6222 | Adalimumab | TNF Receptor |
| LU200134, D2E7, Anti-Human TNF-alpha | ||
| Adalimumab is the first fully human, recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha, MW: 144.19 KD. | ||
| M7387 | TCS 5861528 | TRP Channel |
| Chembridge-5861528 | ||
| TCS 5861528 (Chembridge-5861528) is a potent TRPA1 channel antagonist that antagonizes similarly allyl isothiocyanate- and 4-HNE-evoked TRPA1 responses, with IC50 values of 14.3 μM and 18.7 μM, respectively. | ||
| M9347 | ITI-214 phosphate | PDE |
| ITI214 | ||
| ITI-214 phosphate is an orally active, potent and selective inhibitors of PDE1, exhibits potent PDE1 inhibitory activity (Ki = 58 pM). ITI-214 inhibits recombinant full-length human PDE1A, PDE1B and PDE1C with Kis of 33 pM, 380 pM and 35 pM, respectively. | ||
| M8835 | UA62784 | Others |
| Studies have also reported that UA62784 associates with tubulin at or near the colchicine-binding sites in cells and functions as a cytotoxic, microtubule inhibitor. | ||
| M10335 | IDH-305 | Isocitrate Dehydrogenase (IDH) |
| IDH305 | ||
| IDH-305 is an orally available, mutant-selective and brain-penetrant IDH1 inhibitor that targets IDH1(R132) mutation with IC50 values of 27 nM, 28 nM and 6.14 μM for IDH1R132H, IDH1R132C and IDH1WT, respectively. | ||
| M10546 | Indophagolin | Autophagy |
| Indophagolin is a potent, indoline-containing autophagy inhibitor (IC50=140 nM). Indophagolin antagonizes the purinergic receptor P2X4 as well as P2X1 and P2X3 with IC50s of 2.71, 2.40 and 3.49 μM, respectively. | ||
| M10705 | NVP-2 | CDK |
| NVP-2 is an effective and selective ATP competitive cyclin-dependent kinase 9 (CDK9) probe that inhibits CDK9/CycT activity.IC50 The value is 0.514 nM. NVP-2 has inhibitory effects on CDK1/CycB, CDK2/CycA and CDK16/CycY kinases, which IC50 The values are 0.584 μM, 0.706 μM, and 0.605 μM, respectively. NVP-2 induces apoptosis. | ||
| M10771 | (R)-GNE-140 | LDH |
| (R)-GNE-140 is a selective inhibitor of LDHA and LDHB with IC50 of 3 nM and 5 nM, respectively. (R)-GNE-140 is 18 times more potent than its S-type isomer. | ||
| M11039 | Pyrazoloacridine | Topoisomerase |
| NSC 366140 | ||
| Pyrazoloacridine (NSC 366140) has anticancer activity, inhibiting the activity of topoisomerases 1 and 2 (topoisomerases 1 and 2). Pyrazoloacridine (NSC 366140) on K562 in myeloid leukemia cells IC50 The value is 1.25 μM (24 h). | ||
| M11173 | PC945 | Others |
| PC945 is a potent antifungal triazole drug that is resistant to a variety of sensitive and resistant strains of Aspergillus fumigatus. PC945 is a potent, tightly bound inhibitor of aspergilloxine 14α-demethylase (CYP51A/CYP51B) activity.IC50s are 0.23 μM and 0.22 μM, respectively. | ||
| M11259 | Cefminox sodium | Antibiotic |
| Meicelin, MT-141 | ||
| Cefminox Sodium (MT-141) is a semi-synthetic cephalomycin with a broad spectrum of antibacterial activities. Cefminox sodium (MT-141) is a dual agonist of prostacyclin receptor and PPARγ, which can up-regulate cAMP production and PTEN expression, and inhibit Akt/mTOR signaling pathway. Cefminox sodium (MT-141) can inhibit pulmonary hypertension. | ||
| M14882 | Ibrutinib-biotin | BTK |
| Ibrutinib-biotin is a probe that consists of Ibrutinib linked to biotin via a long chain linker, extracted from patent WO2014059368A1 Compound 1-5, has an IC50 of 0.755-1.02 nM for BTK. | ||
| M21063 | LEO 134310 | Others |
| LEO 134310 is a non-steroidal, selective glucocorticoid receptor (GR) agonist that is being studied in the first phase of plaque psoriasis.LEO 134310 has shown high affinity (EC50 of 14 nM) in GR binding assays.LEO 134310 can be used in dermatological conditions. | ||
| M21079 | Loxoprofenol-SRS tromethamine | COX |
| HR1405–01 | ||
| Loxoprofenol-SRS tromethamine (HR1405-01) is an intravenous NSAID with good anti-inflammatory and analgesic activity. | ||
| M21367 | MB-07803 | Others |
| MB07803 is a potent, non-competitive inhibitor of fructose 1,6-bisphosphatase (FBPase) (EC50: 140 nM, t1/2 of 7.6 ± 2.9 h). | ||
| M21425 | Recombinant Human MIF (E. coli) | Recombinant Proteins |
| Macrophage Migration; Inhibitory Factor | ||
| Recombinant human macrophage migration inhibitor (rhMIF) is a single nonglycosylated polypeptide chain of 115 amino acids produced in Escherichia coli. Accession # P14174. | ||
| M21628 | 2'-Fucosyllactose | IL Receptor/Related |
| 2-FL | ||
| 2'-Fucosyllactose (2'-FL) is an oligosaccharide that could be derived from human milk. 2'-Fucosyllactose regulates the expression of CD14, alleviates colitis and regulates the gut microbiome. 2'-Fucosyllactose stimulates T cells to increase IFN-γ production and decreases IL-6, IL-17, and TNF-α production of cytokines. | ||
| M22463 | Recombinant Human UBA1 Protein (Baculovirus-Insect, His & GST Tag) | Recombinant Proteins |
| Ubiquitin Activating Enzyme E1 | ||
| The recombinant human UBA1/GST chimera consists of 1294 amino acids and has a calculated molecular mass of 146 KDa. A DNA sequence encoding the human UBA1 (NP_003325.2) (Ser 2-Arg 1058) was fused with the N-terminal polyhistidine-tagged GST tag at the N-terminus. | ||
| M25077 | Tarlatamab | Notch |
| AMG-757 | ||
| Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the KDs of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the KDs of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research. | ||
| M25549 | AS 1411 | Others |
| AGRO-100 | ||
| AS1411 is a quadruplex-forming oligonucleotide aptamer that targets nucleolin. AS1411 has anti-tumor activity. | ||
| M27608 | BMS-593214 | Others |
| BMS-593214 is an active site-directed factor (F) VIIa inhibitor. BMS-593214 shows antithrombotic and antihaemostatic properties. BMS-593214 is a direct competitive inhibitor of human FVIIa and a non-competitive inhibitor of Viia-activated substrate FX. BMS-593214 prevents electroinduced carotid artery thrombosis (AT) and wire induced vena cava thrombosis (VT). | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
